tirzepatide vs cagrisema 2.4 mg/2.4 mg shows 23% weight loss in 84 weeks | Michael Weintraub, MD posted on the topic CagriSema vs. Tirzepatide: Which One

While most of the evidence remains preclinical, the authors say GLP-1 receptor agonists could eventually offer benefits for both metabolic health and periodontal disease

Last month, Wegovy received FDA approval for a new indication for use to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight

Husain M, Birkenfeld AL, Donsmark M, for the PIONEER 6 Investigators, et al

Fix: Only bill a separate E/M service when the documentation supports distinct medical decision-making beyond "patient here for injection." Dose adjustments, side effect management, and review of treatment progress all support a separate E/M service, but they must be documented